Epidemiology of Group B Streptococcus: Maternal Colonization and Infant Disease in Kampala, Uganda: Maternal Colonization and Infant Disease in Kampala, Uganda

  • Mary Kyohere
  • , Hannah Georgia Davies
  • , Konstantinos Karampatsas
  • , Liberty Cantrell
  • , Philippa Musoke
  • , Annettee Nakimuli
  • , Valerie Tusubira
  • , Juliet Sendagala Nsimire
  • , Dorota Jamrozy
  • , Uzma Basit Khan
  • , Stephen D. Bentley
  • , Owen B. Spiller
  • , Caitlin Farley
  • , Tom Hall
  • , Olwenn Daniel
  • , Simon Beach
  • , Nick Andrews
  • , Stephanie J. Schrag
  • , Clare L. Cutland
  • , Andrew Gorringe
  • Stephanie Leung, Stephen Taylor, Paul T. Heath, Stephen Cose, Carol Baker, Merryn Voysey, Kirsty Le Doare, Musa Sekikubo, Abdelmajid Djennad, Agnes Nyamaizi, Agnes Ssali, Alexander Amone, Amusa Wamawobe, Carol Nanyunja, Christine Najuka, Cleophas Komugisha, Christine Sseremba, Lydia Nakibuuka, Daniel Kibirige, Dan R. Shelley, Edward A.R. Portal, Ellie Duckworth, Emilie Karafillakis, Geraldine O'hara, Godfrey Matovu, Janet Seeley, Joseph Peacock, Katie Cowie, Lauren Hookham, Madeleine Cochet

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Child survival rates have improved globally, but neonatal mortality due to infections, such as group B Streptococcus (GBS), remains a significant concern. The global burden of GBS-related morbidity and mortality is substantial. However, data from low and middle-income countries are lacking. Vaccination during pregnancy could be a feasible strategy to address GBS-related disease burden. Methods: We assessed maternal rectovaginal GBS colonization and neonatal disease rates in a prospective cohort of 6062 women-infant pairs. Surveillance for invasive infant disease occurred in parallel at 2 Kampala hospital sites. In a nested case-control study, we identified infants <90 days of age with invasive GBS disease (iGBS) (n = 24) and healthy infants born to mothers colonized with GBS (n = 72). We measured serotype-specific anticapsular immunoglobulin G (IgG) in cord blood/infant sera using a validated multiplex Luminex assay. Results: We found a high incidence of iGBS (1.0 per 1000 live births) within the first 90 days of life across the surveillance sites, associated with a high case fatality rate (18.2%). Maternal GBS colonization prevalence was consistent with other studies in the region (14.7% [95% confidence interval, 13.7%-15.6%]). IgG geometric mean concentrations were lower in cases than controls for serotypes Ia (0.005 vs 0.12 μg/mL; P =. 05) and III (0.011 vs 0.036 μg/mL; P =. 07) and in an aggregate analysis of all serotypes (0.014 vs 0.05 μg/mL; P =. 02). Conclusions: We found that GBS is an important cause of neonatal and young infant disease in Uganda and confirmed that maternally derived antibodies were lower in early-onset GBS cases than in healthy exposed controls.
Original languageEnglish
Article numberofaf167
JournalOpen Forum Infectious Diseases
Volume12
Issue number4
DOIs
Publication statusPublished - 1 Apr 2025

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • anticapsular antibody
  • correlate of protection
  • group B Streptococcus
  • invasive disease
  • risk reduction

Fingerprint

Dive into the research topics of 'Epidemiology of Group B Streptococcus: Maternal Colonization and Infant Disease in Kampala, Uganda: Maternal Colonization and Infant Disease in Kampala, Uganda'. Together they form a unique fingerprint.

Cite this